Cable Hill Partners’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Cable Hill Partners’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-400	Closed	-$11K	–	972
2017 Q4	$11K	Buy	+400	New	+$11.2K	﹤0.01%	563

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Cable Hill Partners's RETA Position: Q1 2018 in Review

Cable Hill Partners sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2018, closing a stake of 400 shares — an estimated $11K sold.

Cable Hill Partners first reported a position in RETA in Q4 2017 and held it in 1 quarter. The position peaked at $11K in Q4 2017. 86 funds tracked by Wall St. Rank hold RETA as of Q1 2018.

Cable Hill Partners reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2018 after selling out during the quarter.
Cable Hill Partners sold 400 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2018, an estimated $11K.
Cable Hill Partners first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 1 quarter.
Cable Hill Partners's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $11K in Q4 2017.
86 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.